Fig. 2From: Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney diseaseTreatment effect of atrasentan on HOMA-IR during the SONAR double-blind phase. Note: * p-value for atrasentan versus placebo for all patients combined averaged over visitsBack to article page